Cellebrite sees Q4 revenue $105M-$109M, consensus $106.81M

Sees adjusted EBITDA $25M-$29M. “We delivered a very strong third-quarter performance, highlighted by strong top-line execution, prudent spending and outstanding cash generation,” stated Dana Gerner, Cellebrite’s (CLBT) CFO. “The completion of our broad warrant redemption program, combined with our strong stock price performance over the past several months that resulted in multiple triggering events, enable us to move forward with a more optimized capital structure, an increased stock float and simplified financial reporting. As we look ahead, based on our results for the first three quarters of the year and our assessment of the near-term opportunities, we have raised our 2024 revenue and adjusted EBITDA ranges and increased the low end of our full-year ARR range.”